VUB spin-off PRECIRIX and Evergreen Theragnostics, a radiopharmaceutical contract manufacturer, announced that they have entered into an agreement whereby Evergreen will provide US-based manufacturing for PRECIRIX’s lead product candidate, CAM-H2.
CAM-H2 is being evaluated in a Phase I/II clinical trial targeting breast and gastric cancer. It is based on its unique technology platform using single-domain antibodies found in camelids.